STOCK INFORMATION
PCYC - (NASDAQ)
Jul 2, 2009
at 4:00 PM ET
| Last Sale | $1.26 |
| Change Net | - 0.05 |
| Change % |  3.82% |
| Share Volume | 800 |
| More Information » | |
SHAREHOLDER TOOLS
Shareholder Briefcase |
 Investor Kit |
 News and Event Alerts |
 Download Library |
To Pharmacyclics' knowledge, all press releases and the information contained within them were timely and accurate when issued. The continued accuracy of this material beyond the date of issuance and posting on the website is not assured. Pharmacyclics has no intention of updating this information, and specifically disclaims any duty to do so. These documents may contain forward-looking statements. Actual results could vary dramatically as a result of known and unknown risks and uncertainties. Please see the disclaimer for this website.
ABOUT PHARMACYCLICSPharmacyclics, Inc. (Nasdaq: PCYC) is a pharmaceutical company developing innovative products for cancer and immune mediated diseases. The company is leveraging its small-molecule drug development expertise to build a pipeline in oncology and other diseases based on a wide range of targets, pathways, and mechanisms. The company's products address large markets in oncology and autoimmune diseases. The company is developing several product opportunities derived from structure-based research, including cancer drugs called motexafin gadolinium, histone deacetylase (HDAC) inhibitors, a Factor VIIa inhibitor, which appears to be a novel inhibitor of angiogenesis with potential applications in cancer, and tyrosine kinase inhibitors targeting lymphomas and autoimmune disorders. The company owns the worldwide rights to its drug candidates.
Recent Releases
Jun 5, 2009
Pharmacyclics to Present at the 8th Annual Needham and Company Life Sciences Conference
Jun 1, 2009
Pharmacyclics Files Registration Statement for Rights Offering
Events
 |
Jun 10, 2009 | Needham Life Sciences Conference Webcast |
|
Apr 23, 2009 | Third Quarter Fiscal 2009 Earnings Conference Call |